A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method. (2019)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s12885-019-5801-3
PubMed Identifier: 31242873
Publication URI: http://europepmc.org/abstract/MED/31242873
Type: Journal Article/Review
Volume: 19
Parent Publication: BMC cancer
Issue: 1
ISSN: 1471-2407